$IMGN News
Last published 1y ago
- 1y agoIMGNApproval of Elahere, Bla #761310FDA Approved DrugsApproval Date: 07/14/2025; Drug Name: Elahere, Bla #761310; Active Ingredients: MIRVETUXIMAB SORAVTANSINE-GYNX; Company: Immunogen Inc; Submission Status: Approval; Application Number: 761310
- 1y agoIMGNVRTXAntibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits ResearchGlobeNewswireNew York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates deliver chemotherapy by
- 2y agoABBVCCCCIMGNNVS+1PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial OfficerBusiness WireFormer ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a
- 2y agoABBVCCCCIMGNNVSSeaport Therapeutics Names Lauren White as Chief Financial OfficerBusiness WireFormer ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that
- 2y agoABBVIMGNAbbVie Completes Acquisition of ImmunoGenPR NewswireAbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN). With the completion of the acquisition,...
- 2y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 2y agoPXDIMGNHAICVXKuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 2y agoCEREHAIMGNWAVDKuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoIMGNImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASHBusiness WirePivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated Pivekimab-Containing Triplet Well-Tolerated with
- 2y agoIMGNFDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian CancerBusiness WirePriority Review Granted with PDUFA Date of April 5, 2024 ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food
- 2y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 2y agoIMGNABBVXBI.NBI+6Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billionCNBCOther biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.
- 2y agoABBVIMGNAbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor PortfolioPR NewswireAbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its ...
- 3y agoIMGNImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare ConferenceBusiness WireImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming
- 3y agoIMGNImmunoGen, Inc. (IMGN) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoIMGNImmunoGen Reports Recent Progress and Third Quarter 2023 Financial ResultsBusiness WireContinued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 3y agoIMGNImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerBusiness WireImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing
- 3y agoANIXIMGNGLYCBPMCAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardPR NewswireAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...
- 3y agoIMGNImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating ResultsBusiness WireImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday,
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 3y agoIMGNELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian CancerBusiness WireData Further Position ELAHERE to Become the New Standard of Care for Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Findings to be Highlighted in Oral Presentation at ESGO Annual Congress ImmunoGen
- 3y agoAZNIMGNMRKONCYOn the Road to Halving Cancer: The 2023 Biotech Advancements Igniting HopePR NewswireFN Media Group Presents USA News Group News Commentary VANCOUVER, British Columbia , Sept. 20, 2023 /PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 18, 2023, and in connection with the previously announced
- 3y agoIMGNImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial OfficerBusiness WireImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 3y agoIMGNTAKImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in JapanBusiness WireImmunoGen to Receive $34 Million1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Payments as well as Double-Digit Royalties Collaboration Further
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 3y agoIMGNImmunoGen (IMGN) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoIMGNImmunoGen Announces Departure of Anna Berkenblit, Chief Medical OfficerBusiness WireImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer,
- 3y agoIMGNImmunoGen Reports Recent Progress and Second Quarter 2023 Financial ResultsBusiness WireContinued Strong Momentum with ELAHERE Launch in US; Net Sales of $77.4 Million in Q2 Presented Positive Results for ELAHERE from Phase 3 MIRASOL Trial During Late-Breaking Oral Presentation at ASCO; First Therapy to
- 3y agoIMGNImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth ConferenceBusiness WireImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming
- 3y agoIMGNImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug ConjugatesBusiness WireCollaboration Combines ImmunoGen's Proprietary Linker-Payload Technology with Antibodies Developed by ImmunoBiochem Agreement Grants ImmunoGen an Exclusive License to Existing Antibodies Generated by ImmunoBiochem
- 3y agoIMGNImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug ConjugatesPR NewswireTORONTO, July 24, 2023 /PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced
- 3y agoIMGNImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating ResultsBusiness WireImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of Directors (the
- 3y agoIMGNImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 CongressBusiness WireInterim Analysis from Phase 2 Trial Demonstrates Compelling Anti-Tumor Activity in Patients with Frontline and Relapsed/Refractory BPDCN; No New Safety Signals Identified Enrollment Continues in Frontline CADENZA
- 3y agoPANWDISHMMMCOIN+12Stocks making the biggest moves midday: Palo Alto Networks, 3M, Amedisys, Target and moreCNBCThese are among the stocks posting the largest moves in midday trading Monday.
- 3y agoIMGNELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian CancerBusiness WireResults from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy Clinically Meaningful
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireJune 1, 2023 – ImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company's Board of
- 3y agoDAWNGILDIMGNLEGN+1Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral PresentationsPR NewswireFN Media Group Presents USA News Group News Commentary VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American Society of Clinical
- 3y agoIMGNImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare ConferenceBusiness WireImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical
- 3y agoIMGNImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of
- 3y agoIMGNImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual MeetingBusiness WireData from Confirmatory Trial to be Highlighted in Oral Presentation on Sunday, June 4 ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
- 3y agoIMGNImmunoGen Announces Pricing of Upsized Public Offering of Common StockBusiness WireImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its
- 3y agoIMGNImmunoGen Announces Proposed Public Offering of Common StockBusiness WireImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions,
- 3y agoSBUXGNRCLLYYUM+13Stocks making the biggest moves midday: CVS Health, Eli Lilly, Clorox, Yum and moreCNBCThese are the stocks posting the largest moves midday.
- 3y agoIMGNELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian CancerBusiness WireResults Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer Submission of MAA in
- 3y agoIMGNImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the previously announced appointment of Isabel